Lamivudine/Zidovudine Milpharm

Lamivudine and Zidovudine, the active ingredients in Lamivudine/Zidovudine Milpharm, are nucleoside reverse transcriptase inhibitors presented as an oral tablet formulation for oral use. They treat HIV-1 infection in adults and children as part of antiretroviral therapy.

GNH USA supplies Lamivudine/Zidovudine Milpharm as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine/Zidovudine is used in the management of HIV-1 infection, a retroviral disease requiring combination antiretroviral therapy.

- HIV-1 infection: reduces viral load and helps restore immune function. - Prevention of mother-to-child transmission of HIV: lowers the risk of vertical transmission during pregnancy and delivery. - Pediatric HIV infection: provides an effective component of combination therapy for children living with HIV.

Adverse reactions may occur with Lamivudine/Zidovudine therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Headache: occasional tension-type headaches. - Fatigue: general tiredness or weakness. - Anemia: reduction in red blood cell count. - Neutropenia: lowered neutrophil levels. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Lactic acidosis: buildup of lactate causing metabolic disturbance. - Hepatic steatosis: fatty infiltration of the liver. - Severe bone marrow suppression: pancytopenia requiring medical attention. - Hypersensitivity reactions: rash, fever, or organ involvement. - Pancreatitis: inflammation of the pancreas. - Mitochondrial toxicity: rare muscle weakness or neuropathy.

When prescribing Lamivudine/Zidovudine, clinicians should consider several safety measures. - Monitor blood counts: regular CBC to detect anemia or neutropenia. - Assess liver function: periodic liver enzyme tests for hepatic toxicity. - Avoid in patients with known hypersensitivity to either component. - Use with caution in pregnancy: evaluate risk‑benefit ratio. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lamivudine/Zidovudine may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use with other NRTIs that cause bone marrow suppression (e.g., stavudine). - Combination with didanosine: increased risk of pancreatitis. - Co‑administration with stavine: heightened mitochondrial toxicity.

Moderate Interactions (Monitor Closely): - Protease inhibitors: may alter plasma concentrations of zidovudine. - Non‑nucleoside reverse transcriptase inhibitors (NNRTIs): potential additive toxicity. - Anticoagulants (e.g., warfarin): possible changes in INR requiring monitoring.